Clinical Trials
66 trialsA Study of ASP3082 in Adults With Advanced Solid Tumors
Astellas Pharma Inc
Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer
Montefiore Medical Center
MTAPESTRY 103
Amgen
Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Trishula Therapeutics, Inc.
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
Trishula Therapeutics, Inc.
MK-0482-001
Merck Sharp & Dohme LLC
IntenSify
German Cancer Research Center
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
GlaxoSmithKline
IVY
Eli Lilly and Company
Nab-paclitaxel in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors
Emory University
Study of SRF617 in Patients With Advanced Solid Tumors
Coherus Oncology, Inc.
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
St. Jude Children's Research Hospital
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
Kyowa Kirin Co., Ltd.
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
Sumitomo Pharma America, Inc.
Safety Study of SEA-CD40 in Cancer Patients
Seagen Inc.
IMYO29233
Hoffmann-La Roche
ARCS-Multi
Bayer
Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer
H. Lee Moffitt Cancer Center and Research Institute
ATRiUM
Cambridge University Hospitals NHS Foundation Trust
Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors
Theriva Biologics SL
A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer
Mereo BioPharma
A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer
Eli Lilly and Company
QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel
Altor BioScience
Chloroquine in Combination With Carboplatin/Gemcitabine in Advanced Solid Tumors
University of Cincinnati
Evaluation of Nelfinavir and Chemoradiation for Pancreatic Cancer
University of Iowa
BAY86-9766 Plus Gemcitabine Phase I Study in Asian
Bayer
A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine
Eli Lilly and Company
A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer
Theriva Biologics SL
A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer
University of Michigan Rogel Cancer Center
Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
Oncolytics Biotech
Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer
Milton S. Hershey Medical Center
MK-8776-002
Merck Sharp & Dohme LLC
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers
National Institutes of Health Clinical Center (CC)
Immunochemoradiotherapy in Patients With Pancreatic Cancer
Providence Health & Services
A Study of LY2801653 in Advanced Cancer
Eli Lilly and Company
Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer
Bayer
Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors
Traws Pharma, Inc.
Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder
Oncolytics Biotech
A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors
Hoffmann-La Roche
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
Merrimack Pharmaceuticals
A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid Tumors
Hoffmann-La Roche
Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma
Progen Pharmaceuticals
A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors
Altor BioScience
A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors
Sanofi
HAI Abraxane With Gemcitabine and Bevacizumab
M.D. Anderson Cancer Center
Ultrasound-assisted Treatment of Inoperable Pancreatic Cancer
Haukeland University Hospital
A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies
Exelixis
Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors
PharmaMar
A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors
Sanofi